The thing to remember is, the road to share price appreciation does not start at the first FDA meeting. Any number of news events, pre-clinical results, uplisting, and/or new associations, etc., could move us up nicely well before any FDA meeting. Of course, a vacuum of such things would likely see share price decline.
best to all.